

## Research Article

### Evaluating the Necessity of Level IIb Dissection in Oral Squamous Cell Carcinoma: A Retrospective Cohort Study in an Iraqi Population

Sargon Shazo 

Department of Oral and Maxillofacial Surgery, College of Dentistry, University of Duhok, Duhok, Iraq

Author email: [sargon.shazo@uod.ac](mailto:sargon.shazo@uod.ac)


#### Article History

Received: 10 June 2025

Revised: 22 August 2025

Accepted: 2 October 2025

Published online: 15 September 2026



**Copyright:** © 2026 Authors.

This is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY 4.0) license (<https://creativecommons.org/licenses/by/4.0/>).

#### Abstract

**Aims:** This study aimed to evaluate the necessity of level IIb dissection in patients within an Iraqi cohort.

**Materials and Methods:** The histopathological and clinical data of 50 patients with oral squamous cell carcinoma (29 males and 21 females), treated between June 2018 and June 2020, were analyzed. Histopathological studies were conducted on 857 lymph nodes, including 143 from level IIb, after immunohistochemical staining with cytokeratin 5/6. Statistical tests assessed predictors of level IIb involvement.

**Results:** Level IIb involvement was observed in only 2 cases (4%) with concurrent level IIa metastasis. No isolated level IIb involvement was detected. Primary tumor location ( $p = 0.03$ ) was a significant predictor of level IIb involvement. Other variables, such as age ( $p\text{-value} = 0.2675$ ), sex ( $p\text{-value} = 0.503$ ), grade ( $p\text{-value} = 0.1$ ), DOI ( $p\text{-value} = 0.617$ ), size ( $p\text{-value} = 0.319$ ), and neck status ( $p\text{-value} = 0.099$ ), showed no significant association with level IIb involvement.

**Conclusion:** Routine dissection of level IIb is unnecessary in clinically negative oral squamous cell carcinoma cases and should be reserved for clinically positive or advanced diseases. Further studies incorporating advanced diagnostics are needed to refine clinical guidelines.

**Keywords:** Level IIb, Lymph node metastasis, Oral Cancer, Shoulder Dysfunction

**How to cite:** Shazo S. Evaluating the Necessity of Level IIb Dissection in Oral Squamous Cell Carcinoma: A Retrospective Cohort Study in an Iraqi Population. Al-Rafidain Dent J. 2026;26(2):508-525.

## INTRODUCTION

Oral squamous cell carcinoma (OSCC) is among the most prevalent head and neck cancers. (1) representing a significant global health challenge, with nearly 390,000 new cases annually, including over 300 new cases every year in Iraq (2). Tumor characteristics, treatment modalities, and host defense influence the prognosis of OSCC; however, regional lymph node metastasis reduces the survival rate by half and is considered the most significant survival factor (3).

Along with surgical management of primary cancer, neck dissection is done in therapeutic and elective settings to increase the survival rate and improve regional control of the disease (3).

Memorial Sloan Kettering Cancer Center initially proposed a description of neck levels, which Suen and Goepfert later subdivided into sublevels at MD Anderson Center (4,5).

Originally, neck dissection was based on the fact that OSCC has a predictable lymphatic pathway for metastasis, with levels I, II, and III carrying the highest risk, underscoring the necessity of selective neck dissection (6).

In 1880, Kocher introduced an approach for removing nodal metastasis. Later, in 1906, George Crile refined it with a series of 132 neck dissections and described the classical radical neck dissection (7,8).

Shoulder dysfunction is one of the most frequent problems in patients undergoing neck dissection, whether selective or comprehensive. This is mainly due to the nerve retraction to extirpate nodes in this area, as the spinal accessory nerve crosses level II and divides it into level IIa anterior to the nerve and level IIb lying postero-medially to the nerve (9). Different opinions about the added value of dissecting level IIb in selective neck dissection have been raised because of the added morbidity, time, and therapeutic benefits (10,11). Studies have shown improved quality of life, better shoulder function, and comparable locoregional control when level IIb was spared (12,13).

Due to the frequent incidence of shoulder dysfunction among Iraqi patients after neck dissection, the present study aimed to evaluate the necessity of routinely including level IIb in neck dissection for OSCC patients by studying their histopathological samples after immunohistopathologic staining with cytokeratine5/6. To the best of the author's knowledge, this is the first study to be carried out on an Iraqi population.

## **MATERIALS AND METHODS**

### **Ethical approval**

This study was conducted in accordance with the principles outlined in the Declaration of Helsinki for research ethics. Ethical approval to use human material and data was granted by the Research Ethics Committee of the Duhok General Health Directorate, with license number (05022025-2-3), on the fifth of February, 2025; the patients' consent to participate was waived by the committee.

This is a retrospective cohort study. Clinical data and histopathological samples were collected from case sheets and biopsies of 50 patients diagnosed with OSCC, including 29 male and 21 female patients between 25 and 80 years old. All patients underwent surgery at Ghazi Al-Hariri Teaching Hospital for Surgical Specialties, Baghdad/Iraq between June 2018 and June 2020. Patients with a history of preoperative chemotherapy or radiotherapy and incomplete clinical or histopathological samples were excluded from the study.

The data collected comprised clinical examination and imaging (head and neck computed tomography (CT), chest radiograph, abdominal ultrasound) performed on all patients. Sex, age, and tumor information were gathered from the patient records. Clinical and Pathological staging was implemented according to the 7th edition of the American Joint Committee on Cancer (AJCC) tumor lymph node metastasis (TNM) staging system (14), as shown in Tables 1 and 2.

Table (1). TNM staging system according to AJCC.<sup>(14)</sup>

| <b>T Category</b>  | <b>T Criteria</b>                                                                                                                                                                                                                                                                                                                                                     |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TX                 | Primary tumor cannot be assessed                                                                                                                                                                                                                                                                                                                                      |
| Tis                | Carcinoma <i>in situ</i>                                                                                                                                                                                                                                                                                                                                              |
| T1                 | Tumor $\leq 2$ cm with a depth of invasion (DOI)* $\leq 5$ mm                                                                                                                                                                                                                                                                                                         |
| T2                 | Tumor $\leq 2$ cm with DOI* $> 5$ mm<br>or tumor $> 2$ cm and $\leq 4$ cm with DOI* $\leq 10$ mm                                                                                                                                                                                                                                                                      |
| T3                 | Tumor $> 2$ cm and $\leq 4$ cm with DOI* $> 10$ mm<br>or tumor $> 4$ cm with DOI* $\leq 10$ mm                                                                                                                                                                                                                                                                        |
| T4                 | Moderately advanced or very advanced local disease                                                                                                                                                                                                                                                                                                                    |
| T4a                | Moderately advanced local disease<br>Tumor $> 4$ cm <u>with</u> DOI* $> 10$ mm<br>or tumor invades adjacent structures only (e.g., through cortical bone of the mandible or maxilla or involves the maxillary sinus or skin of the face)<br>Note: Superficial erosion of bone/tooth socket (alone) by a gingival primary is not sufficient to classify a tumor as T4. |
| T4b                | Very advanced local disease<br>Tumor invades masticator space, pterygoid plates, or skull base and/or encases the internal carotid artery                                                                                                                                                                                                                             |
| <b>cN Category</b> | <b>cN Criteria</b>                                                                                                                                                                                                                                                                                                                                                    |
| NX                 | Regional lymph nodes cannot be assessed                                                                                                                                                                                                                                                                                                                               |
| N0                 | No regional lymph node metastasis                                                                                                                                                                                                                                                                                                                                     |
| N1                 | Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension<br>ENE <sup>1</sup> (-)                                                                                                                                                                                                                                                          |
| N2                 | Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE (- <sup>2</sup> );<br>or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE (-);<br>or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, and ENE (-)           |
| N2a                | Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension, and ENE (-)                                                                                                                                                                                                                                                  |
| N2b                | Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension, and ENE (-)                                                                                                                                                                                                                                                                    |
| N2c                | Metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, and ENE (-)                                                                                                                                                                                                                                                        |
| N3                 | Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE (-);<br>or metastasis in any node(s) and clinically overt ENE (+ <sup>3</sup> )                                                                                                                                                                                                             |
| N3a                | Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE (-)                                                                                                                                                                                                                                                                                         |
| N3b                | Metastasis in any node(s) and clinically overt ENE (+)                                                                                                                                                                                                                                                                                                                |
| <b>M Category</b>  | <b>M Criteria</b>                                                                                                                                                                                                                                                                                                                                                     |
| cM0                | No distant metastasis                                                                                                                                                                                                                                                                                                                                                 |
| cM1                | Distant metastasis                                                                                                                                                                                                                                                                                                                                                    |
| pM1                | Distant metastasis, microscopically confirmed                                                                                                                                                                                                                                                                                                                         |

<sup>1</sup> ENE = Extra-nodal extension;<sup>2</sup> (-) = negative<sup>3</sup> (+) = positive

Table (2). AJCC Prognostic Stage Groups<sup>(14)</sup>

| Stage | When T is...    | And N is... | And M is... |
|-------|-----------------|-------------|-------------|
| 0     | Tis             | N0          | M0          |
| I     | T1              | N0          | M0          |
| II    | T2              | N0          | M0          |
| III   | T3              | N0          | M0          |
| III   | T1, T2, T3      | N1          | M0          |
| IVA   | T4a             | N0, N1      | M0          |
| IVA   | T1, T2, T3, T4a | N2          | M0          |
| IVB   | Any T           | N3          | M0          |
| IVB   | T4b             | Any N       | M0          |
| IVC   | Any T           | Any N       | M1          |

### Surgical Management and Sample Collection

Samples were collected from patients with OSCC treated surgically by excision of the primary lesion; the procedure involved excision of the primary lesion with a 1- 1.5 cm margin for curative intent. Reconstruction was attained by primary closure, skin grafting, and local or regional flaps. Neck dissection was performed based on clinical criteria and National Comprehensive Cancer Network (NCCN) guidelines, whether selective or comprehensive (15).

Histopathological samples were collected from archival tissue blocks retained at the Department of Pathology in Ghazi Al-Hariri Teaching Hospital for Surgical Specialties. The samples processed and diagnosed between June 2018 and June 2020 were enrolled in the study. The inclusion criteria included formalin-fixed, paraffin-embedded (FFPE) tissue blocks with a histopathologically confirmed diagnosis of OSCC and neck dissection, good preservation, and paired hematoxylin and eosin (H&E)-stained slides available. The samples with poor preservation, incomplete clinical data, or inadequate volume of tissue for additional analysis were excluded.

Sample identification numbers were accessed from the laboratory information management system (LIMS). Demographic and clinical data, including age of patient, sex, clinical diagnosis, site of biopsy, and date of procedure, were accessed from laboratory records and anonymized to preserve confidentiality.

### **Histopathological Analysis**

The collected pathological specimens were processed using hematoxylin and eosin (H&E) staining for tumor grading and staging.

An immunohistochemical study using cytokeratin (CK5/CK6) staining was conducted on paraffin-embedded tissue sections. Antigen retrieval and staining procedures followed standard protocols, and two independent consultant pathologists validated the results. Tumor staining intensity was categorized using the Dako Omnis scoring system (Agilent Technologies, Santa Clara, CA, USA, distinguishing between positive and negative cases according to manufacturer instructions.

The depth of invasion (DOI) was measured as the perpendicular distance from the adjacent normal tissue's basement membrane to the tumor invasion's deepest point. The World Health Organization (WHO) grading system was used to categorize tumors into well-differentiated, moderately differentiated, and poorly differentiated grades (16).

### **Statistical Analysis**

Data were analyzed using SPSS version 25 and R version 4.5.1. Data completeness and normality were assessed using visual inspection and the Shapiro–Wilk test. Continuous variables were reported as mean  $\pm$  SD for normally distributed data and median (IQR) for skewed data. Associations between categorical variables were assessed using the chi-square or Fisher's exact test, while independent t-tests and Mann–Whitney U tests were used for continuous variables as appropriate. Statistical significance was set at  $P < 0.05$ , with 95% confidence intervals calculated where appropriate.

## **RESULTS**

Fifty patients, comprising 21 females (42%) and 29 males (58%), aged between 25 and 84, were included in this study. The mean age was 59.3 years  $\pm$  12.98, as shown in Figure 1. The tongue was the most frequently involved site, with 19 cases (38%), followed by buccal mucosa, with 17 cases (34%), as illustrated in Figure 2. Buccal

mucosa was the most commonly affected site in males (41.38%), while the tongue was the most affected in females (38.1%) (Figure 3). The depth of invasion ranged from 2 to 14 mm, with a median of 6 mm (IQR5-8). DOI was stratified into 3 categories, and in most cases (78%), DOI exceeded 5 mm, as shown in Table 3.




Figure (1). Sex distribution of patients by number and percentage




Figure (2). Percentage Subsite distribution of cancer cases




Figure (3). Percentage of Subsite distribution according to sex




Figure (4). Proposed decision-making algorithm for level IIb dissection in oral squamous cell carcinoma

Table (3). Distribution of patient data

| Category                  | Count | Percentage |
|---------------------------|-------|------------|
| <b>Grade</b>              |       |            |
| Well Differentiated       | 22    | 44         |
| Moderately Differentiated | 16    | 32         |
| Poorly Differentiated     | 12    | 24         |
| <b>Stage</b>              |       |            |
| IVA                       | 21    | 42         |
| III                       | 13    | 26         |
| II                        | 10    | 20         |
| I                         | 3     | 6          |
| IVB                       | 3     | 6          |
| <b>Depth of invasion</b>  |       |            |
| 5–9.99 mm                 | 33    | 66         |
| 0–4.99 mm                 | 11    | 22         |
| ≥10 mm                    | 6     | 12         |

Twenty-two cases (44%) were well differentiated at presentation, 16 (32%) were moderately differentiated, and 12 were poorly differentiated. Concerning the tumor stage, 21 cases (42%) were stage IVA (Table 3).

In this study, 29 patients (58%) had clinically negative lymph nodes (cN0) at the time of presentation, while 21 (42%) had clinically positive lymph nodes (cN+).

Out of 50 patients included in the study, 20 (40%) underwent unilateral supra-omohyoid neck dissection (SOHND), 26 (52%) had extended SOHND, 2 (4%) had unilateral Comprehensive Neck Dissection (CND), and 2 underwent bilateral SOHND. Eight hundred fifty-seven lymph nodes were examined, with an average of 17.14 nodes per neck dissection. Of these, 143 lymph nodes were extirpated from level IIB, with an average of 2.86 (143/50 patients).

Eight of 29 patients (27.6%) who were cN0 at presentation had occult metastasis, with an average of 2 nodes per patient, all in level IIa; however, none of the cN0 patients had level IIb involvement pathologically. The total number of patients with pathologically positive nodes (pN+) included in the study was 29 patients (58%). The rate of extracapsular lymphatic extension was 8%, with 4 cases involved (Table 4).

Out of 50 patients included in the study, level IIb involvement was observed in only 2 cases (4%). Notably, both cases exhibited concomitant level IIa involvement, and no isolated level IIb involvement was detected. In all patients with clinically node-negative (cN0) disease, no metastasis to level IIb was seen, while the clinically node-positive (cN+) group demonstrated a 9.5%; 2 of 21 cN+ patients had level IIb involvement (Table 4).

Table (4). Characteristics of lymph nodes studied

| Category                          | Count | Percentage |
|-----------------------------------|-------|------------|
| <b>Clinically Positive LN</b>     |       |            |
| Positive                          | 21    | 42         |
| Negative                          | 29    | 58         |
| <b>Pathologically Positive LN</b> |       |            |
| Positive                          | 29    | 58         |
| Negative                          | 21    | 42         |
| <b>Extracapsular extension</b>    |       |            |
| Positive                          | 4     | 8          |
| Negative                          | 46    | 92         |
| <b>Level IIb involvement</b>      |       |            |
| Positive                          | 2     | 4          |
| Negative                          | 48    | 96         |

A significant association was found between tumor site and level IIb lymph node (LN) involvement (p-value < 0.05, Chi-square test). On the other hand, there was no significance for other variables like age (p-value > 0.05, T-test), sex (p-value > 0.05, Fisher's test), grade (p-value > 0.05 Chi-square), DOI (p-value > 0.05, Mann-Whitney U), and size (p-value > 0.05, Mann-Whitney U) as predictor for level IIb involvement (Tables 5 and 6).

Table (5). Significance of variables with normal distribution as a predictor for level IIb involvement

| Variable | p-value | Test Used  |
|----------|---------|------------|
| Age      | 0.2675  | T-test     |
| Subsite  | 0.03    | Chi-square |
| Grade    | 0.1     | Chi-square |

Table (6). Significance of variables with skewed distribution as a predictor for level IIb involvement

| Variable                       | IIB Negative (n=48)                                         | IIB Positive (n=)             | p-value      | Test Used      |
|--------------------------------|-------------------------------------------------------------|-------------------------------|--------------|----------------|
| Tumor size (cm)                | 4.2 [3.5–5.0]                                               | 3.5 [3.2–3.8]                 | 0.319        | Mann-Whitney U |
| Depth (mm)                     | 6.0 [5.0–8.0]                                               | 7.0 [6.5–7.5]                 | 0.617        | Mann-Whitney U |
| Clinically +ve <sup>§</sup> LN | 0.0 [0.0–1.0]                                               | 1.0 [1.0–1.0]                 | 0.099        | Mann-Whitney U |
| Pathologically +ve LN          | 1.0 [0.0–3.0]                                               | 9.5 [8.2–10.8]                | <b>0.022</b> | Mann-Whitney U |
| Sex                            | F <sup>†</sup> : 21 (43.8%);<br>M <sup>‡</sup> : 27 (56.2%) | F: 0 (0.0%);<br>M: 2 (100.0%) | 0.503        | Fisher's Exact |
| ECE* (positive)                | 4 (8%)                                                      | 1 (50%)                       | 0.192        | Fisher's Exact |

<sup>§</sup>+ve: positive; <sup>†</sup>F: female; <sup>‡</sup>M: male; \*ECE: extracapsular extensi

## DISCUSSION

In OSCC, lymphatic metastasis is the single most important prognostic factor, reducing the survival rate by 50% (17). It typically follows a predictable pathway mainly to levels I, II, and III, and sometimes to levels VI and V (18).

Since the early 20th century, neck dissection, as a therapeutic concept, underwent a major revolutionary development to increase the survival rate and decrease the

associated comorbidities (19). However, despite all efforts to circumvent complications, they still do occur, and the argumentative issue of the extent of neck dissection is still an area of debate and research (13).

One of the frequent complications of neck dissection, especially in elective procedures, is shoulder dysfunction ranging from 10-100% in comprehensive neck dissection (CND) and 9-25% in SND, imposing a direct relation between the extent of surgery and post-operative outcome (20,21). The cause of dysfunction can be attributed to direct injury to the spinal accessory nerve or excessive traction to facilitate access to the area for good clearance (9,21).

In their 11-year retrospective study of 389 cN0 OSCC patients, Duvernay, J. et al. (22) found no evidence of metastasis in level IIb. These findings agree with the results of this study, in which level II was not involved in all cN0 patients; however, only 2 of 21 cN+ patients (9.5%) had level IIb involvement. These data challenge the therapeutic benefits of dissecting level IIb when compared to the quality of life associated with the increased prevalence of patients with shoulder dysfunction

Immunohistochemical staining has been found to be advantageous for detecting micrometastases in lymph nodes. (22–24) Therefore, immunohistochemical staining using cytokeratin 5/6 was implemented in all study samples to enhance the detection sensitivity.

### **Subsites of the primary**

Two cases out of 50 (retromolar trigon, buccal mucosa) showed metastatic deposits in level IIb, and there was a significant relation between subsite and level IIb involvement ( $p$ -values = 0.03); anatomical proximity could be a possible cause for such results. Other studies revealed that subsites could be a significant predictor; however, the tongue and gingivo-buccal sulcus were the most significant subsites with a metastatic propensity to level IIb involvement (25–27). These disparities in results can be attributed to differences in sample size and methodology.

**Lymph nodes**

There was an association between the clinical status of lymph nodes cN+ and level IIb lymphatic involvement; however, this relation did not reach statistical significance (p-value = 0.09). No evidence of skip lymphatic metastases was observed in the studied samples. In the only cases where region IIb was involved, concomitant level IIa involvement was present, making the clinical involvement level IIa a strong indication for dissection of the entire level II. The findings were consistent with results from previous studies, where a strong association was found between level IIa positivity and level IIb metastasis (9,25,26,28–33).

**Depth of invasion**

Although the depth of invasion(DOI) is considered an independent predictor for early lymphatic metastasis (34–36), this study's results showed no significant impact of DOI as a predictor for region IIb involvement, especially in cN0 cases. These results align with data from previous studies that did not show a direct relation between DOI and level IIb involvement or the possibility of skip metastasis to this region (31,33,37–39).

On the other hand, clinicopathological variables like sex, grade, and size were not significant predictors of involvement of level IIb. The limited sample size might have affected the significance of the results, though data from this research align with data from other studies with larger sample sizes (9,40).

**Clinical implications**

According to our findings, a pragmatic decision-making strategy for level IIb neck dissection in oral SCC is suggested, considering the primary tumor subsite and clinical neck status (Figure 4). For patients with a clinically positive neck (cN+), standard inclusion of level IIb dissection seems appropriate. For cN0 clinically negative necks, a more judicious strategy can be applied: level IIb dissection can be advocated for retromolar trigone or other posterior location tumors, such as posterolateral tongue. For the rest of tumor locations, intraoperative frozen section analysis of level IIa nodes can guide the decision; in case of no metastasis, level IIb dissection avoidance could be

safe. This technique strives to reduce accessory nerve manipulation morbidity without compromising oncologic outcomes in adequately selected patients.

## CONCLUSIONS

Within the limitations of this study:

The routine dissection of level IIb is not recommended, particularly on an elective basis for clinically negative lymph nodes (cN0). However, for therapeutic neck dissection, where clinical node involvement is evident, dissection of level IIb is highly recommended. Advanced-stage disease, tumor subsite, and certain pathological features may increase the likelihood of this level of involvement. Future research, comprising more extensive multicenter studies employing advanced molecular diagnostics, imaging modalities, and other biomarkers to refine the results and strengthen the decision, is recommended.

## Acknowledgment

The author would like to express sincere gratitude to Professor Dr. Bahar Jaafar, Dr. Teroj Abdulrahman, and Professor Dr. Faeza Aftan for their invaluable assistance in preparing this manuscript.

## Authors' Contribution

Shazo S contributed to conceptualization, formal analysis, funding acquisition, investigation, methodology, project administration, resources, software, validation, visualization, writing—original draft, writing—review and editing.

## Ethical statement:

Ethical approval to use human material and data was granted by the Research Ethics Committee of the Duhok General Health Directorate, with license number (05022025-2-3), on the fifth of February, 2025; the patients' consent to participate was waived by the committee.

## Conflict of interest

The author declares that there are no conflicts of interest regarding the publication of this manuscript.

**Availability of data and materials:** All data generated or analyzed during this study are included in this published article.

## Declaration of Generative AI and AI-assisted technologies

While preparing this work, the author used ChatGPT 4.0 and Grammarly (Grammarly Inc.) web service to improve the manuscript's readability and correct grammatical issues. After using this tool, the author reviewed and edited the content as needed and takes full responsibility for the content of the published article.

**REFERENCES**

- 1 . Shah JP. Introduction to Head and Neck Cancer. In: Shah JP, Patel SG, Singh B, Wong R, editors. Jatin Shah's Head and Neck Surgery and Oncology. fifth edit. Elsevier; 2019. p. 1–14 .
- 2 . WHO International Agency for Research on Cancer. GLOBOCAN 2022 [Internet]. 2022. Available from: <http://gco.iarc.fr/today/home>
- 3 . Andrew T. Meram and Brian M. Woo. Oral Cancer Management. In: Michael Miloro, G. E. Ghali, Peter E. Larsen PW, editor. 4th ed. Springer; 2022. p. 1015–50 .
- 4 . Suen JY, Goepfert H. Editorial. Standardization of neck dissection nomenclature. Head & Neck Surg [Internet]. 1987;10(2):75–7. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/hed.2890100202>
- 5 . Shah JP. Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am J Surg [Internet]. 1990 Oct 1;160(4):405–9. Available from: [https://doi.org/10.1016/S0002-9610\(05\)80554-9](https://doi.org/10.1016/S0002-9610(05)80554-9)
- 6 . Shaw RJ, Brown J, Ettl T, Risk JM. Prognostic Factors in Oral, Oropharyngeal, and Salivary Gland Cancer. In: Brennan P, Schliephake H, Ghali GE, Cascarini L, editors. Maxillofacial Surgery. 3rd ed. Elsevier; 2017. p. 257–74 .
- 7 . Ward BB, Helman JI. Squamous Cell Carcinoma of the Oral and Maxillofacial Region. In: Fonseca RJ, editor. Oral and Maxillofacial Surgery. 3rd ed. Elsevier; 2018. p. 670–89 .
- 8 . Martin H, Del Valle B, Ehrlich H, Chahan WG. Neck dissection. Cancer. 1951;441–99 .
- 9 . Bhattacharya A, Adwani D, Adwani N, Sharma V. Is it worthy? Removal of level IIB nodes during selective neck dissection (I-III) for oral carcinomas. Ann Maxillofac Surg. 2015;5(1):20 .
- 10 . Mauramati S, Veneroni MV, Errico E, Canzi P, Bertino G, Robiolio E, et al. Selective neck dissection of level IIB in cN0 laryngeal cancer: a systematic review and meta-analysis. Eur Arch oto-rhino-laryngology Off J Eur Fed Oto-Rhino-Laryngological Soc Affil with Ger Soc Oto-Rhino-Laryngology - Head Neck Surg. 2024.

- 11 . Sakai A, Nonaka T, Furuya H, Ebisumoto K, Sugimoto R, Maki D, et al. Shoulder function after neck dissection with level IIb preservation: a prospective observational study. *Acta Otolaryngol.* 2023 Sep;143(9):814–22 .
- 12 . Rastogi S, Sharma A, Choudhury R, Tripathi S, Al Wayli H, Amrithraj A, et al. Is Superselective Neck Dissection Safer Than Supraomohyoid Neck Dissection for Oral Carcinoma Patients With N0 Neck in Terms of Shoulder Morbidity and Recurrence Rate? *J Oral Maxillofac Surg* [Internet]. 2018 Mar 1;76(3):647–55. Available from: <https://doi.org/10.1016/j.joms.2017.08.002>
- 13 . Celik B, Coskun H, Kumas FF, Irdesel J, Zarifoglu M, Erisen L, et al. Accessory nerve function after level 2b–preserving selective neck dissection. *Head Neck* [Internet]. 2009 Nov 1;31(11):1496–501. Available from: <https://doi.org/10.1002/hed.21112>
- 14 . Edition E. 8th AJCC Cancer Staging Form Supplement 6-2018 update. *AJCC Cancer Staging Manual, 8th Ed* [Internet]. 2018;(Junio):192–4. Available from: [https://cancerstaging.org/references-tools/deskreferences/Documents/AJCC Cancer Staging Form Supplement.pdf](https://cancerstaging.org/references-tools/deskreferences/Documents/AJCC_Cancer_Staging_Form_Supplement.pdf)
- 15 . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) Head and Neck Cancers [Internet]. 2019. Available from: [www.NCCN.org](http://www.NCCN.org)
- 16 . Bhargava A, Saigal S, Chalishazar M. Histopathological Grading Systems In Oral Squamous Cell Carcinoma: A Review. *J Int Oral Heal.* 2010;2(4):1–10 .
- 17 . Shah JP. cervical lymph nodes. In: Shah J, Patel SG, Singh G, Wong R, editors. *Jatin Shah's Head and Neck Surgery and Oncology.* fifth edit. Elsevier; 2019. p. 441–88 .
- 18 . Shah JP. Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. *Am J Surg.* 1990;160(4):405–9 .
- 19 . Ferlito A, Silver CE, Rinaldo A. Neck Dissection in the New Era. *J Am Coll Surg* [Internet]. 2007;204(3). Available from: [https://journals.lww.com/journalacs/fulltext/2007/03000/neck\\_dissection\\_in\\_the\\_new\\_era.18.aspx](https://journals.lww.com/journalacs/fulltext/2007/03000/neck_dissection_in_the_new_era.18.aspx)
- 20 . Giordano L, Sarandria D, Fabiano B, Del Carro U, Bussi M. Shoulder function after selective and superselective neck dissections: clinical and functional outcomes. *Acta*

Otorhinolaryngol Ital organo Uff della Soc Ital di Otorinolaringol e Chir Cerv-facc. 2012 Dec;32(6):376–9 .

- 21 . Gane EM, Michaleff ZA, Cottrell MA, McPhail SM, Hatton AL, Panizza BJ, et al. Prevalence, incidence, and risk factors for shoulder and neck dysfunction after neck dissection: A systematic review. *Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol*. 2017 Jul;43(7):1199–218 .
- 22 . Yoshida K, Kashima K, Suenaga S, Nomi N, Shuto J, Suzuki M. Immunohistochemical detection of cervical lymph node micrometastases from T2N0 tongue cancer. *Acta Otolaryngol*. 2005;125(6):654–8 .
- 23 . Yi CH, Zhai Q, Wang BY. Updates on immunohistochemical and molecular markers in selected head and neck diagnostic problems. *Arch Pathol Lab Med*. 2017;141(9):1214–35 .
- 24 . Park JM, Jung CK, Choi YJ, Lee KY, Kang JH, Kim MS, et al. The use of an immunohistochemical diagnostic panel to determine the primary site of cervical lymph node metastases of occult squamous cell carcinoma. *Hum Pathol* [Internet]. 2010;41(3):431–7. Available from: <http://dx.doi.org/10.1016/j.humpath.2009.09.001>
- 25 . Dabholkar JP, Kapre NM. Level IIb Neck Dissection in Oral Cavity Cancers- When Should One Address it.? *Indian J Surg Oncol* [Internet]. 2016;7(3):303–6. Available from: <http://dx.doi.org/10.1007/s13193-015-0461-5>
- 26 . Chheda YP, Pillai SK, Parikh DG, Dipayan N, Shah S V., Alaknanda G. A Prospective Study of Level IIB Nodal Metastasis (Supraretrospinal) in Clinically N0 Oral Squamous Cell Carcinoma in Indian Population. *Indian J Surg Oncol*. 2017;8(2):105–8 .
- 27 . Bartella AK, Kloss-Brandstätter A, Kamal M, Teichmann J, Modabber A, Hölzle F, et al. “IIb or not IIb” - The necessity of dissection in patients with oral squamous cell carcinoma. *J cranio-maxillo-facial Surg Off Publ Eur Assoc Cranio-Maxillo-Facial Surg*. 2016 Oct;44(10):1733–6 .
- 28 . Chebib E, Eymerit C, Chabbert-Buffet N, Angelard B, St Guily JL, Périé S. High rate of IIA/IIB neck groups involvement supports complete lateral neck dissection in thyroid carcinoma. *Gland Surg*. 2020;9(6):1973–81 .

- 29 . Chakraborty PS, Das AK, Vatsyayan A, Rahman T, Das R, Medhi SK, et al. Metastatic involvement of level IIb nodal station in oral squamous cell carcinoma: A clinicopathological study. *Natl J Maxillofac Surg*. 2019;10(1):8–12 .
- 30 . Ghantous Y, Akrish S, Abd-Elraziq M, El-Naaj IA. Level IIB Neck Dissection in Oral Squamous Cell Carcinoma: Science or Myth? *J Craniofac Surg*. 2016 Jun;27(4):1035–40 .
- 31 . Li Y, Liu K, Ke Y, Zeng Y, Chen M, Li W, et al. Risk Factors Analysis of Pathologically Confirmed Cervical Lymph Nodes Metastasis in Oral Squamous Cell Carcinoma Patients with Clinically Negative Cervical Lymph Node: Results from a Cancer Center of Central China. *J Cancer*. 2019;10(13):3062–9 .
- 32 . Soni S, Soni TP, Patni N. Association between nodal metastasis and histopathological factors in postoperative gingivo-buccal complex squamous cell carcinoma: A Retrospective Study. *Gulf J Oncolog*. 2019;(29):66–71 .
- 33 . Taha IA, Younis WH. Clinicopathological Analysis of Oral Squamous Cell Carcinoma in Iraq during Period (2001 - 2013). *J Baghdad Coll Dent*. 2015;27(2):58–65 .
- 34 . Fukano H, Matsuura H, Hasegawa Y, Nakamura S. Depth of invasion as a predictive factor for cervical lymph node metastasis in tongue carcinoma. *Head Neck*. 1996;19(3):205–10 .
- 35 . Moore C, Kuhns JG, Greenberg RA. Thickness as Prognostic Aid in Upper Aerodigestive Tract Cancer. *Arch Surg*. 1986;121(12):1410–4 .
- 36 . Faisal M, Bakar MA, Sarwar A, Adeel M, Batool F, Malik KI, et al. Depth of invasion (DOI) as a predictor of cervical nodal metastasis and local recurrence in early-stage squamous cell carcinoma of oral tongue (ESSCOT). *PLoS One*. 2018;13(8):1–10 .
- 37 . Trehan S, Patel K, Shukla H, Tripathi U, Tadaia M. The effect of depth of invasion and tumour size on risk of neck node metastasis in squamous cell carcinoma of oral cavity: retrospective analysis. *J Res Med Dent Sci*. 2015;3(3):213 .
- 38 . Mair MD, Shetty R, Nair D, Mathur Y, Nair S, Deshmukh A, et al. Depth of invasion, size and number of metastatic nodes predicts extracapsular spread in early oral cancers with occult metastases. *Oral Oncol*. 2018;81(April):95–9 .

- 39 . Shazo S, Dakheel Al-Mualla H, Muayad Abdulkarem A, Aftan Zghair F. The Correlation Between Depth of Invasion and Degree of Differentiation with Cervical Lymph Node Metastasis in Oral Squamous Cell Carcinoma. J Contemp Med Sci. 2023;9(6):394–401 .
40. Yurong K, Tengfei Zhao, Huang S, Liu J, Duan W, Wang Y, et al. Cervical level iib metastases in squamous cell carcinoma of the oral cavity: a systematic review and meta-analysis. Onco Targets Ther [Internet]. 2017;4475–83. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602281/pdf/ott-10-4475.pdf>

## تقييم ضرورة استئصال المستوى الثاني ب في سرطان الخلايا الحشفية الفموية: دراسة أترابية استرجاعية في السكان العراقيين

سركون شازو

قسم جراحة الفم والوجه والفكين، كلية طب الأسنان، جامعة دهوك، دهوك، العراق

### الملخص

**الأهداف:** هدفت هذه الدراسة إلى تقييم ضرورة استئصال العقد اللمفاوية من المستوى الثاني (ب) لدى المرضى ضمن مجموعة عراقية. **المواد وطرائق العمل:** تم تحليل البيانات النسيجية والسريية لخمسين مريضاً مصاباً بسرطان الخلايا الحشفية الفموية (29 ذكراً و 21 أنثى)، والذين عولجوا بين يونيو 2018 ويونيو 2020. أجريت دراسات نسيجية على 857 عقدة لمفاوية، منها 143 عقدة من المستوى الثاني (ب)، بعد التلوين المناعي النسيجي باستخدام السيبتوكيراتين 6/5. قُيِّمت الاختبارات الإحصائية مؤشرات التنبؤ بانتشار الورم إلى المستوى الثاني (ب). **النتائج:** لوحظ انتشار الورم إلى المستوى الثاني (ب) في حالتين فقط (4%) مع وجود نقائل متزامنة إلى المستوى الثاني (أ). لم يُرصد أي انتشار منفرد للورم إلى المستوى الثاني (ب). كان موقع الورم الأولي (قيمة  $p = 0.03$ ) مؤشراً هاماً للتنبؤ بانتشار الورم إلى المستوى الثاني (ب). لم تُظهر متغيرات أخرى، مثل العمر (قيمة  $p = 0.2675$ )، والجنس (قيمة  $p = 0.503$ )، ودرجة الورم (قيمة  $p = 0.1$ )، وعمق الغزو (قيمة  $p = 0.617$ )، والحجم (قيمة  $p = 0.319$ )، وحالة العنق (قيمة  $p = 0.099$ )، أي ارتباط ذي دلالة إحصائية مع إصابة العقد اللمفاوية من المستوى IIb. **الاستنتاجات:** لا داعي للاستئصال الروتيني للعقد اللمفاوية من المستوى IIb في حالات سرطان الخلايا الحشفية الفموية ذات الأعراض السريية السلبية، وينبغي حصره في الحالات ذات الأعراض السريية الإيجابية أو المتقدمة. هناك حاجة إلى مزيد من الدراسات التي تتضمن تقنيات تشخيص متقدمة لتحسين الإرشادات السريية.

**الكلمات المفتاحية:** المستوى IIb، نقائل العقد اللمفاوية، سرطان الفم، خلل وظائف الكتفالكلمات المفتاحية: الدقة، نموذج الأسنان، رانتج صديق للبيئة، رانتج نباتي، طباعة ثلاثية الأبعاد، خصائص ميكانيكية.